About
Antifibrinolytic Therapy for Acute Bleeding Conditions
PamBio is a biotechnology company developing drug therapy for hemorrhagic stroke (e.g. intracranial bleeding and ICH) and other acute bleeding conditions. PamBio's solution for ICH drug treatment is an inactive recombinant mutant-tPA protein. Its S481A amino-acid substitution renders the protein catalytically inactive but maintains its structure and ability to interact with major components of the fibrinolytic pathway. In essence, the mutant-tPA drug molecule is a competitive inhibitor to the native-tPA. This therapeutic biomolecule has a dual antifibrinolytic and neuroprotective effect. It blocks both tPA and uPA fibrinolysis enzyme activity, enabling treatment beyond three hours, and it limits tPA and glutamate-mediated neurotoxicity by blocking the binding of the neurotoxic tPA to NMDA receptors, thus providing neuroprotection. PamBio is an NGT3 VC portfolio company.
Identity
| Name | PamBio |
|---|---|
| Slug | pambio |
| Type / kind | startup |
| Crunchbase ID | pambio |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOPbrZkJDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Jan 2019 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Nazareth |
| HQ address | Wadi el-Haj St 13, Nazareth, Israel |
Classifications
Funding
| Total raised | $10.0M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}